Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Name: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Published: 2020
License: Public Domain

Merck Sharp & Dohme LLC · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

esophageal squamous cell carcinoma (escc), gastroesophageal junction carcinoma (gejc), esophageal adenocarcinoma (eac), programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), programmed death-ligand 2 (pdl2, pd-l2), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Related documents